Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
Douglas L. Mann(Cardiovascular Research Center), Thomas R. Fleming(Cornell University), John J.V. McMurray(Western Infirmary), Luigi Tavazzi(Cornell University), Wilson S. Colucci(Cornell University), Lars Køber(University of Copenhagen), Anders Waldenström(Cornell University), Faı̈ez Zannad(Inserm), Milton Packer(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Marshelle Warren(Amgen (United States)), Markku S. Nieminen(Cornell University), Jeffrey Borer(Cornell University), Jacques Djian(Cornell University), Karl Swedberg(Sahlgrenska University Hospital), Peter Liu(Cornell University), Dirk Jan van Veldhuisen(University of Groningen), Henry Krum(Monash University), Arthur M. Feldman(Temple University), Helmut Drexler(Medizinische Hochschule Hannover), Arne Westheim(Cornell University)
Cited by 1,228
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k